文献速递细菌感染、耐药与抗菌药物

奥利万星模拟暴露在体外药效学模型中选择出对奥利万星敏感性降低的耐甲氧西林金黄色葡萄球菌,但与其他抗菌药物的交叉耐药或跷跷板效应极小

Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

在体外药效学模型中模拟奥利万星1200 mg静脉单次给药后的平均游离药物暴露,对5株金黄色葡萄球菌(含4株MRSA)作用28天。奥利万星暴露对5/5菌株杀菌2-17天后出现低敏感亚群再生长,4/5菌株最终MIC升至敏感性折点以上;万古霉素和达托霉素MIC升高2-8倍但多数未超折点,β-内酰胺类MIC基本不变。耐药主要与purR突变相关。

要点

  • 奥利万星模拟暴露对5/5金黄色葡萄球菌杀菌2-17天后出现低敏感亚群再生长。
  • 4/5菌株最终奥利万星MIC升至敏感性折点以上(>0.125 mg/L),最早5天可检出低敏感株。
  • 万古霉素和达托霉素MIC升高2-8倍但多数未超折点,β-内酰胺类MIC基本不变。

核心结论

  • 奥利万星选择出的耐药主要与purR突变相关,与达巴万星选择出的耐药相比,交叉耐药和walK突变较少见。
  • 其原因尚不清楚,可能源于机制差异和不同的突变通路。

研究设计与样本

  • 体外药效学模型,模拟奥利万星1200 mg静脉单次给药后的平均游离药物暴露(fCmax 11.2 µg/mL;β相消除半衰期13.4小时;γ相消除半衰期245小时),作用28天,针对5株金黄色葡萄球菌(含4株MRSA)。

主要发现

  • 奥利万星暴露对5/5菌株杀菌2-17天后出现低敏感亚群再生长。
  • 最早5天可检出对奥利万星敏感性降低的分离株,4/5菌株最终MIC升至敏感性折点以上(>0.125 mg/L)。
  • 万古霉素和达托霉素MIC升高2-8倍,但多数分离株未超过敏感性折点。
  • 对奥利万星敏感性降低的回收分离株中,β-内酰胺类MIC基本不变。
  • 突变多样但常涉及purR,4/5菌株中鉴定出13个独特变异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dalbavancin exposures select for VAN and daptomycin cross-resistance in Staphylococcus aureus often by walK-related mutations. Oritavancin is another long-acting lipoglycopeptide, but its proclivity to select for cross-resistance is unknown. The objective of this study was to determine if post-distributional pharmacokinetic oritavancin exposures select for meaningful susceptibility changes in S. aureus. METHODS: We simulated average post-distributional, free-drug exposures of oritavancin 1200 mg IV once (fCmax 11.2 µg/mL; β-elimination t1/2 13.4 h; γ-elimination t1/2 245 h) in an in vitro pharmacodynamic model for 28 days against five S. aureus including four MRSA. Samples were taken daily for colony enumeration and resistance screening. Susceptibility testing was repeated on isolates from resistance screening plates against oritavancin, vancomycin, daptomycin, dalbavancin and 6 beta-lactams with varying penicillin-binding protein affinities. RESULTS: Tested oritavancin exposures were bactericidal against 5/5 strains for 2-17 days before regrowth of less-susceptible subpopulations occurred. Isolates with reduced susceptibility to oritavancin were detected as early as 5 days, but the MIC increased above the susceptibility breakpoint (>0.125 mg/L) in 4/5 strains eventually. Vancomycin and daptomycin MICs increased by 2- to 8-fold but did not exceed the susceptibility breakpoints in most isolates. β-lactam MICs were largely unchanged among the recovered isolates with reduced oritavancin susceptibility. Mutations were diverse but often involved purR with 13 unique variants identified among 4/5 strains. CONCLUSIONS: Oritavancin-selected resistance was primarily associated with purR mutation and less frequently associated with cross-resistance and walK mutation than dalbavancin-selected resistance in similar strains and conditions. The reason for this is unclear but may stem from differences in the mechanism(s) and divergent mutational pathways.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Werth BJ, Zhang R, Barreras Beltran IA, et al. Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials. J Antimicrob Chemother. 2025. PMID: 39936452. doi:10.1093/jac/dkaf042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。